What Is Ipamorelin? Growth Hormone Research Peptide Guide (2026)
Every major advance in GH secretagogue research has come from researchers asking the same question about each new compound: what does it do that its predecessors don’t? GHRP-6 released GH through a newly discovered receptor pathway but also spiked cortisol, prolactin, and appetite. Hexarelin produced stronger GH release than GHRP-6 but with broader hormonal off-target effects and rapid receptor desensitization. Each compound revealed something important about the GHS-R1a receptor biology — and each one’s limitations showed researchers exactly what the next compound needed to improve.
Ipamorelin was the answer to those limitations. Developed by Novo Nordisk and first characterized by Raun et al. in 1998, it is described in the original publication as “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH” — meaning it was the first compound to activate GHS-R1a and produce meaningful GH release without triggering the cortisol, ACTH, and prolactin elevation that had limited the research utility of earlier GHRPs. That selectivity profile is what distinguishes Ipamorelin from every compound that came before it and makes it the reference compound for selective GHS-R1a pharmacology research today.
What Ipamorelin Is
Ipamorelin is a synthetic pentapeptide — five amino acids — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its molecular weight is 711.85 Da and its CAS number is 170851-70-4. The compound was developed at Novo Nordisk A/S through structure-activity relationship optimization of earlier GHRP scaffolds, with the specific goal of retaining GHS-R1a agonist activity while eliminating the cortisol, ACTH, prolactin, and appetite stimulation that characterized GHRP-6 and Hexarelin.
The name reflects its position in the GHRP development lineage: it is a penta (five amino acid) -morelin (GH secretagogue) compound. Its unusual amino acid composition — including an alpha-aminoisobutyric acid (Aib) at position 1 and D-2-naphthylalanine (D-2-Nal) at position 3, both non-natural amino acid variants — is what gives it both its receptor selectivity and its resistance to enzymatic degradation compared to earlier GHRPs with more conventional sequences.
Compound specifications:
| Property | Detail |
|---|---|
| Common name | Ipamorelin |
| Developer | Novo Nordisk A/S |
| First described | Raun et al., 1998 |
| Amino acids | 5 (pentapeptide) |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular weight | 711.85 Da |
| CAS number | 170851-70-4 |
| Receptor target | GHS-R1a (ghrelin receptor) |
| GH release selectivity | High — no significant ACTH, cortisol, or prolactin elevation |
| Appetite stimulation | Minimal — unlike GHRP-6 |
| GH peak (animal models) | Approximately 40 minutes post-administration |
| FDA approval status | Not approved — Category 1 restoration February 2026 |
| Supplied form | Lyophilized powder |
| Vial size | 2mg |
| Storage lyophilized | -20°C up to 24 months |
| Storage reconstituted | 2-8°C up to 28 days |
The GHS-R1a Receptor — Why It Matters
Understanding Ipamorelin requires understanding the receptor it activates and why that receptor’s pharmacology is scientifically significant. GHS-R1a — the growth hormone secretagogue receptor type 1a — is a G protein-coupled receptor expressed primarily on somatotroph cells of the anterior pituitary and on hypothalamic neurons in the arcuate nucleus. It is the same receptor that endogenous ghrelin — the “hunger hormone” produced primarily in the stomach — activates as its primary CNS target.
The discovery of GHS-R1a followed directly from the development of synthetic GHRP compounds. GHRP-6 was developed first, before anyone knew what receptor it activated. The search for that receptor led to GHS-R1a’s cloning in 1996. The existence of GHS-R1a then prompted researchers to search for the endogenous ligand — which turned out to be ghrelin, discovered in 1999. The synthetic pharmacology preceded and enabled the discovery of the endogenous hormone.
Ipamorelin activates GHS-R1a through the same molecular cascade as ghrelin but with a different pharmacological profile. When Ipamorelin binds GHS-R1a on pituitary somatotrophs, it triggers Gq/11-mediated phospholipase C activation, which generates inositol trisphosphate (IP3) and causes calcium mobilization from intracellular stores. This calcium release drives GH-containing secretory vesicle fusion with the somatotroph cell membrane, producing pulsatile GH secretion into the bloodstream. The GH peak in animal models occurs approximately 40 minutes post-administration — a well-characterized pharmacokinetic parameter documented by Gobburu et al. (PMID: 10496658).
What Ipamorelin does not do — and this is its defining research characteristic — is significantly activate the broader neuroendocrine signaling networks that earlier GHRPs engaged at their GH-releasing concentrations. Published data from the original Raun et al. characterization and subsequent studies shows that Ipamorelin does not significantly elevate ACTH, cortisol, prolactin, FSH, LH, or TSH even at doses more than 200-fold above the GH-releasing ED50. This extraordinary hormonal selectivity is what the 1998 Raun paper was specifically describing when it characterized Ipamorelin as the first selective GH secretagogue.
Ipamorelin vs. Earlier GHRPs — The Selectivity Story
The GHRP family’s development represents a clear trajectory toward greater selectivity, and understanding where Ipamorelin sits in that trajectory explains why it is the reference compound for GHS-R1a pharmacology research.
GHRP-6 — the founding compound, developed in 1984 — activates GHS-R1a and releases GH but also elevates cortisol, ACTH, prolactin, and produces strong appetite stimulation through the ghrelin receptor’s appetite-related functions. It is scientifically valuable for studying the intersection of GH release and appetite regulation because ghrelin itself does both — but it is not selective for GH release alone.
Hexarelin — more potent than GHRP-6 in terms of acute GH release but with the broadest off-target hormonal effects of the GHRP family and the most pronounced receptor desensitization with repeated administration. It also has GH-independent cardioprotective effects through the CD36 receptor — a distinct and scientifically interesting mechanism, but one that complicates research designs where GHS-R1a selectivity is required.
Ipamorelin — the same GHS-R1a mechanism as its predecessors but without the cortisol, ACTH, prolactin, and appetite stimulation. This clean pharmacological profile is what makes it the preferred compound for research where isolated GH axis modulation is the endpoint, because any observed effects can be attributed to GHS-R1a-mediated GH release rather than confounded by simultaneous cortisol or ACTH elevation.
| Compound | GHS-R1a | Cortisol/ACTH | Prolactin | Appetite | Selectivity |
|---|---|---|---|---|---|
| GHRP-6 | Yes | Yes (significant) | Yes | Strong | Low |
| Hexarelin | Yes | Yes (significant) | Yes | Moderate | Low |
| GHRP-2 | Yes | Yes (moderate) | Yes | Moderate | Moderate |
| Ipamorelin | Yes | No (minimal) | No | Minimal | High |
The CJC-1295 and Ipamorelin Combination — Why Researchers Use Both
The most commonly studied Ipamorelin research combination involves CJC-1295 — a GHRH analog that activates the GHRH receptor on pituitary somatotrophs through a completely independent pathway from GHS-R1a. Understanding why the combination produces synergistic rather than simply additive GH release requires understanding the two pathways’ molecular mechanisms.
CJC-1295 activates the GHRH receptor, triggering Gs-mediated adenylyl cyclase activation and intracellular cyclic AMP (cAMP) accumulation. This cAMP-dependent pathway enhances GH gene transcription and primes somatotrophs for secretion but does not directly trigger calcium-dependent vesicle exocytosis. Ipamorelin activates GHS-R1a, triggering the Gq/11-mediated calcium mobilization cascade that does directly drive vesicle exocytosis.
When both pathways are activated simultaneously, the cAMP signal from CJC-1295 enhances the somatotroph’s readiness for secretion while the calcium signal from Ipamorelin triggers that secretion — the two converge on GH release through different intracellular mechanisms rather than through the same pathway twice. The result is a GH output that substantially exceeds what either compound produces alone — a well-characterized synergistic relationship that has made this combination a standard research protocol for studying maximal GH axis stimulation.
Additionally, Ipamorelin suppresses somatostatin release from the hypothalamus — somatostatin being the primary inhibitory regulator of GH secretion — which further amplifies the GH release produced by the combined protocol. Three simultaneous effects: GHRH receptor activation (CJC-1295), GHS-R1a activation (Ipamorelin), and somatostatin suppression (Ipamorelin) all converging on pituitary GH output.
Published Research — What the Data Shows
Ipamorelin has a meaningful published research base spanning animal model pharmacology, preclinical physiology, and human clinical trial data. The human data is limited but real — which places Ipamorelin in a more clinically grounded position than many research peptides.
Raun et al. 1998 — The founding characterization: The original Novo Nordisk paper established Ipamorelin’s GHS-R1a selectivity, documenting its GH-releasing potency and confirming the absence of significant ACTH, cortisol, and prolactin elevation across dose ranges more than 200-fold above the GH-releasing ED50. This selectivity characterization remains the foundational reference for Ipamorelin’s research utility.
Bone density research: Multiple preclinical studies documented Ipamorelin’s effects on bone formation. An 8-week administration study in female rats showed increased cortical bone mineral density and periosteal bone formation rate without adverse resorption markers (Svensson et al., 2000). A separate study documented stimulation of longitudinal bone growth in animal models (Johansen et al., PMID: 10373343). These findings reflect GH and IGF-1-mediated effects on bone rather than direct bone cell receptor activity.
Body composition research: Preclinical studies in diet-induced obese rat models showed Ipamorelin reducing fat mass while preserving lean body mass at a magnitude comparable to direct recombinant GH administration (Johansen et al., 1999) — reflecting downstream IGF-1-mediated anabolic and lipolytic effects.
Phase 2 human clinical trial: A 2014 Phase 2 randomized controlled trial (n=87) published in International Journal of Colorectal Disease (Beck et al., PMID: 25331030) evaluated Ipamorelin for postoperative ileus management in bowel resection patients — representing the most rigorous published human study to date and providing pharmacokinetic and safety data in a clinical population.
Regulatory Status in 2026 — Important Context
Ipamorelin’s regulatory status has shifted significantly in early 2026 and is worth understanding precisely for researchers tracking the compound’s availability.
In 2023, the FDA placed Ipamorelin on its Category 2 bulk drug substances list, effectively blocking licensed compounding pharmacies from preparing it for patient use. This restriction created significant disruption for clinical users who had been accessing Ipamorelin through compounding pharmacies with physician prescriptions.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that Ipamorelin would be among approximately 14 peptides moved from Category 2 back to Category 1, restoring legal access through licensed compounding pharmacies with a physician’s prescription. This reclassification does not constitute FDA drug approval. Ipamorelin remains an unapproved drug under FDA regulations — it is simply no longer prohibited from compounding pharmacy preparation.
For laboratory research, this regulatory context is background information rather than a primary concern. Research-grade Ipamorelin has continued to be available for legitimate laboratory research use throughout both regulatory periods under the research use only framework that governs the research peptide supply market separately from pharmacy compounding regulations.
Research Applications
Ipamorelin is examined in laboratory settings across several interconnected GH axis and growth physiology research domains. GHS-R1a pharmacology research uses Ipamorelin as the reference selective agonist for studying GHS-R1a receptor activation, downstream calcium mobilization, and pulsatile GH release dynamics in isolation from the confounding cortisol, ACTH, and appetite effects that limit the research specificity of earlier GHRPs.
Comparative GHRP research uses Ipamorelin alongside GHRP-6, GHRP-2, and Hexarelin to characterize how structural modifications across the GHRP family alter receptor selectivity, hormonal off-target profiles, and GH release potency — providing a clean research framework for structure-activity relationship investigations in the GH secretagogue class. GH axis combination research examines the synergistic GH output produced when Ipamorelin is combined with GHRH analogs like CJC-1295, studying how the two independent pathways — GHS-R1a calcium mobilization and GHRH receptor cAMP signaling — converge on somatotroph GH release to produce supraphysiological output.
Bone formation research uses Ipamorelin’s documented effects on cortical bone mineral density and longitudinal bone growth in animal models to investigate how GH/IGF-1 axis activation mediates bone anabolic responses. Body composition research examines fat mass reduction and lean mass preservation in preclinical obesity models. Postoperative physiology research draws on the 2014 Phase 2 clinical trial data examining Ipamorelin’s effects in post-surgical patients.
Format, Handling and Storage
Ipamorelin (2mg) is supplied as lyophilized powder in a sterile glass vial. Reconstitute with bacteriostatic water by running the solvent slowly down the inside wall of the vial and allow 5 to 10 minutes of passive dissolution without agitation. Do not shake or vortex. A properly reconstituted solution should be completely clear and colorless. Store lyophilized vials at -20°C, protected from light and moisture, for up to 24 months. Allow sealed vials to equilibrate to room temperature before opening to prevent moisture condensation. Once reconstituted, refrigerate at 2 to 8°C immediately and use within 28 days. Do not freeze reconstituted solutions.
Frequently Asked Questions
What is Ipamorelin? Ipamorelin is a synthetic pentapeptide (five amino acids) developed by Novo Nordisk and first described by Raun et al. in 1998 as the first selective growth hormone secretagogue. It activates GHS-R1a — the ghrelin receptor on pituitary somatotrophs — to produce pulsatile GH release without significant elevation of cortisol, ACTH, prolactin, or appetite stimulation, making it the most selective compound in the GHRP research class. For laboratory research use only.
How does Ipamorelin work? Ipamorelin binds GHS-R1a on pituitary somatotrophs, triggering Gq/11-mediated phospholipase C activation, IP3 generation, and intracellular calcium mobilization. This calcium release drives GH secretory vesicle exocytosis, producing pulsatile GH release. Ipamorelin simultaneously suppresses somatostatin — the primary inhibitor of GH secretion — amplifying the net GH output. GH peaks approximately 40 minutes post-administration in animal models.
What is the difference between Ipamorelin and GHRP-6? Both activate GHS-R1a and release GH. GHRP-6 also significantly elevates cortisol, ACTH, and prolactin and produces strong appetite stimulation — limiting its use in research requiring isolated GH axis modulation. Ipamorelin produces no significant cortisol, ACTH, or prolactin elevation even at doses more than 200 times above the GH-releasing threshold, making it the preferred tool for GH axis research where hormonal selectivity is required.
Why is Ipamorelin combined with CJC-1295 in research? CJC-1295 activates the GHRH receptor through a cAMP-dependent pathway. Ipamorelin activates GHS-R1a through a calcium-dependent pathway. The two mechanisms converge on GH release through different intracellular routes, producing synergistic output that substantially exceeds what either compound achieves alone. This combination is the standard research protocol for studying maximal GH axis stimulation through dual-pathway activation.
Is Ipamorelin FDA approved? No. Ipamorelin is not FDA-approved for any medical indication. On February 27, 2026, it was moved from FDA Category 2 back to Category 1, restoring access through licensed compounding pharmacies with a physician’s prescription. This reclassification does not constitute FDA approval. For laboratory research, Ipamorelin is available under the research use only framework.
Where can I buy research-grade Ipamorelin? Patriot Peptides Ipamorelin (2mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility. Batch-specific Certificates of Analysis are available. For laboratory research use only.
All content is for informational and educational purposes only. All Patriot Peptides products are strictly for laboratory research use only. Not for human consumption, veterinary use, or clinical application.
Related reading: CJC-1295 vs Ipamorelin: Research Comparison | What Are Research Peptides? | How to Store Lyophilized Peptides | Are Research Peptides Legal in the USA?